DEFINITIONS OF BIOCHEMICAL FAILURE THAT BEST PREDICT CLINICAL FAILURE IN PATIENTS WITH PROSTATE CANCER TREATED WITH EXTERNAL BEAM RADIATION ALONE: A MULTI-INSTITUTIONAL POOLED ANALYSIS
- 1 March 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 173 (3), 797-802
- https://doi.org/10.1097/01.ju.0000152556.53602.64
Abstract
Pooled data on 4,839 patients with T1-2 prostate cancer treated with external beam radiation therapy (RT) alone at 9 institutions have previously provided long-term biochemical failure (BF) and clinical outcomes using the American Society for Therapeutic Radiology and Oncology (ASTRO) definition. In this report we determined the sensitivity and specificity of several BF definitions using distant failure (DF) alone or clinical failure (CF), defined as local failure (LF) and/or DF. The pooled cohort was treated between 1986 and 1995 with external beam RT (60 Gy or greater) without pre-RT androgen suppression or planned post-RT adjuvant androgen suppression. Median followup was 6.3 years. The sensitivity and specificity of 102 definitions of BF relative to DF and LF were assessed. The BF definitions with higher sensitivity and specificity than the ASTRO definition for DF only and CF are reported. The sensitivity and specificity of the ASTRO definition to predict DF alone was 55% and 68%, respectively. Three definitions had higher sensitivity and specificity, namely prostate specific antigen (PSA) greater than current nadir (lowest PSA prior to current measurement) plus 3 ng/ml (sensitivity 76% and specificity 72%), dated at the call (failure date as the date when the criterion was met), PSA greater than absolute nadir plus 2 ng/ml (sensitivity 72% and specificity 70%), dated at the call, or 2 consecutive increases of at least 0.5 ng/ml, back dated (sensitivity 69% and specificity 73%). The sensitivity and specificity of the ASTRO definition to predict CF was 60% and 72%, respectively. Three definitions had higher sensitivity and specificity, namely PSA greater than current nadir plus 3 ng/ml (sensitivity 66% and specificity 77%), dated at the call, PSA greater than absolute nadir plus 2 ng/ml (sensitivity 64% and specificity 74%), dated at the call, or 2 consecutive increases of at least 0.5 ng/ml, back dated (sensitivity 67% and specificity 78%). Using what is to our knowledge the largest data set of patients with prostate cancer treated with RT alone we correlated multiple definitions of BF with the strict clinical end points of DF alone and CF (DF or local failure). Defining BF as PSA greater than absolute nadir plus 2 ng/ml, dated at the call, PSA greater than current nadir plus 3 ng/ml, dated at the call, or 2 consecutive increases of at least 0.5 ng/ml, back dated, had higher sensitivity and specificity for DF alone or CF compared with the ASTRO definition. This information should contribute to the discussion regarding suggested modifications to the ASTRO definition of biochemical failure.Keywords
This publication has 17 references indexed in Scilit:
- Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA eraInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995International Journal of Radiation Oncology*Biology*Physics, 2003
- Modifying the American Society for Therapeutic Radiology and Oncology Definition of Biochemical Failure to Minimize the Influence of Backdating in Patients With Prostate Cancer Treated With 3-dimensional Conformal Radiation Therapy AloneJournal of Urology, 2003
- A STANDARD DEFINITION OF DISEASE FREEDOM IS NEEDED FOR PROSTATE CANCER: UNDETECTABLE PROSTATE SPECIFIC ANTIGEN COMPARED WITH THE AMERICAN SOCIETY OF THERAPEUTIC RADIOLOGY AND ONCOLOGY CONSENSUS DEFINITIONJournal of Urology, 2002
- Definitions of biochemical failure in prostate cancer following radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- The definition of biochemical failure in patients treated with definitive radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Radiation Therapy for Clinically Localized Prostate CancerJama-Journal Of The American Medical Association, 1999
- Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1998
- The Correlation Between the Astro Consensus Panel Definition of Biochemical Failure and Clinical Outcome for Patients with Prostate Cancer Treated with External Beam IrradiationInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical controlInternational Journal of Radiation Oncology*Biology*Physics, 1996